

IN THE CLAIMS

Claims 1-20. (Canceled).

Claim 21. (Currently amended) ~~The modified Factor VIII polypeptide of claim 20,~~
A modified Factor VIII polypeptide having a Factor VIII:C activity, wherein (I) the
modified Factor VIII polypeptide has at least one modification in at least one A3 domain
portion, wherein the portion is selected from the group of portions, based upon the
human sequence, consisting of amino acids (i) 1743 (Phe) to 1749 (Arg), (ii) 1784 (Ser)
to 1831 (Asp), (iii) 1888 (Ser) to 1919 (His), (iv) 1942 (Trp) to 1947 (Met), and (v) 1959
(Ser) to 1974 (Ala), wherein the modification is an amino acid substitution, deletion or
addition, and wherein the modification reduces the binding to low-density lipoprotein
receptor protein (LRP), wherein the modified Factor VIII polypeptide further comprises
and (II) at least one modification in at least one C1 domain portion, wherein the portion
is selected from the group of portions, based upon the human sequence, consisting of
amino acids (i) 2037 (Ile) to 2062 (Trp), (ii) 2108 (Asp) and 2118 (Asn), and (iii) 2154
(Thr) to 2158 (Ile), wherein the modification is an amino acid substitution, deletion or
addition.

Claim 22. (Currently amended) The modified Factor VIII polypeptide of claim
[[20]] 21, wherein the modified Factor VIII polypeptide further comprises at least one
modification in at least one C2 domain portion, wherein the portion is selected from the
group of portions, based upon the human sequence, consisting of amino acids (i) 2209
(Arg) to 2234 (Phe) and (ii) 2269 (His) to 2281 (Lys), wherein the modification is an
amino acid substitution, deletion or addition.

Claim 23. (Currently amended) The modified Factor VIII polypeptide of claim
[[20]] 21, wherein the modified Factor VIII polypeptide is produced by recombinant
techniques.

Claim 24. (Previously presented) A preparation comprising:

- (A) a modified Factor VIII polypeptide having a Factor VIII:C activity, wherein the modified Factor VIII polypeptide has at least one modification in at least one A3 domain portion, wherein the portion is selected from the group of portions, based upon the human sequence, consisting of amino acids (i) 1743 (Phe) to 1749 (Arg), (ii) 1784 (Ser) to 1831 (Asp), (iii) 1888 (Ser) to 1919 (His), (iv) 1942 (Trp) to 1947 (Met), and (v) 1959 (Ser) to 1974 (Ala), wherein the modification is an amino acid substitution, deletion or addition, and wherein the modification reduces the binding to low-density lipoprotein receptor protein (LRP); and
- (B) a lipoprotein receptor protein antagonist.

Claim 25. (Previously presented) The preparation according to claim 24, wherein the lipoprotein receptor protein antagonists are selected from the group consisting of receptor-associated protein (RAP) and a fragment of lipoprotein receptor protein from clusters I, II, III or IV, wherein the fragment binds to a Factor VIII-LRP binding site.

Claim 26. (Previously presented) The preparation according to claim 24, wherein the modified Factor VIII polypeptide further comprises at least one modification in at least one C1 domain portion, wherein the portion is selected from the group of portions, based upon the human sequence, consisting of amino acids (i) 2037 (Ile) to 2062 (Trp), (ii) 2108 (Asp) and 2118 (Asn), and (iii) 2154 (Thr) to 2158 (Ile), wherein the modification is an amino acid substitution, deletion or addition.

Claim 27. (Previously presented) The preparation according to claim 24, wherein the modified Factor VIII polypeptide further comprises at least one modification in at least one C2 domain portion, wherein the portion is selected from the group of portions, based upon the human sequence, consisting of amino acids (i) 2209 (Arg) to 2234 (Phe) and (ii) 2269 (His) to 2281 (Lys), wherein the modification is an amino acid substitution, deletion or addition.

Claim 28. (Previously presented) The preparation of claim 24, wherein the modified Factor VIII polypeptide is produced by recombinant techniques.